Uzbekistan's Ministry of Health said in a statement that 18 children who died had consumed cough syrup Doc-1 Max. This medicine is made by Noida based Marion Biotech.
New Delhi: Uzbekistan has claimed that 18 children died after consuming cough syrup made in India. After this, India has started the investigation of a Noida-based pharmaceutical company on Tuesday. It was said on Tuesday that several children were given Doc-1 Max tablets and syrup made by Marion Biotech, after which they died.
Criminal case registered after the death of 18 children
“On the death of 18 children after taking Doc-1 Max drug, a complaint has been filed against Kuramax Medical Company and state-centre experts and officials of standardization of drugs,” the SSS said in a statement from Tashkent to UrduPoint News/Sputnik. A criminal case has been initiated, alleging under Article 186-3 of the Criminal Code (violation of orders for the retail sale of drugs containing potent substances).
According to local media reports, the chemical ethylene glycol was found in the cough syrup during the lab test. This is the same chemical found in the cough syrup and it has been said to be poisonous. In the past also, the same chemical was found in cough syrup in the death of children in Gambia after drinking cough syrup. Another Indian company – Haryana-based Maiden Pharma – is under investigation for cough syrup containing the same chemical. There were 70 deaths from Maiden’s cough syrup in Gambia, but it was not clear in the investigation.
Diethylene glycol (DEG) and ethylene glycol (EG) are highly toxic colorless and viscous liquids with a sweet taste. According to the Centers for Disease Control, DEG and EG are often found as toxic ingredients in glycerin, which is used by many pharmaceutical companies as a sweetener in the manufacture of syrups.
India is set to probe the claims that the deaths of 18 children in Uzbekistan were linked to the syrup manufactured by Noida-based Marion Biotech.
The central drugs regulatory team has got in touch with the Uttar Pradesh drugs licensing authority to initiate the inquiry against the drug-maker, officials said
The joint inquiry will be conducted by the Central and state drugs regulatory teams, it is learnt.